🇺🇸 FDA
Pipeline program

Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

GS-US-418-3899

Phase 3 small_molecule active

Quick answer

Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP for Ulcerative Colitis (UC) is a Phase 3 program (small_molecule) at Alfasigma S.p.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Alfasigma S.p.A.
Indication
Ulcerative Colitis (UC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials